Federal Drug Administration

The Federal Drug Administration is presented as a weakened regulatory institution whose failure transformed scientific uncertainty into commercial certainty. Rather than stopping Phalanx, the vaccine marketed as protection against rabies, it approved the product in an atmosphere of political pressure, public fear, and institutional eagerness for a reassuring solution. Its decision made the agency an important link between the epidemic, the state, and the industries that profited from collective panic.

Institutional Weakness and Political Pressure

The Federal Drug Administration is described as severely underfunded and mismanaged when Phalanx was submitted for approval. Its weakness was compounded by an exceptionally business-friendly administration that wanted a “magic bullet” and treated rapid authorization as evidence of decisive leadership. The vaccine was pushed through the agency in two months, while the administration publicly claimed that testing in Europe had already settled the substantive questions and that only domestic bureaucracy had caused delay.

The political presentation of the approval mattered as much as the procedure itself. The president framed the issue as a choice between obstructive government and large-scale protection, giving the Federal Drug Administration’s decision the aura of an emergency safeguard rather than the appearance of a compromised review. The result was immediate: the company’s initial public offering rose 389 percent on its first day. Regulatory approval thus functioned not only as a medical judgment but also as a market signal and a political spectacle.

Phalanx and the Failure of Verification

The agency’s failure becomes clearest in the account of Phalanx’s creators. They conceived the product as a preventive vaccine because fear would make people continue buying prevention even when they showed no symptoms. They had access to biomedical contacts and political connections, expected to produce a prototype within a month, and prepared their proposal within days. The Federal Drug Administration did not meaningfully interrupt that process; the product was advanced through the system before its true nature had been established.

The people behind Phalanx defend themselves through technical language. They insist that they never explicitly lied: they had been told the disease was rabies, so they made a rabies vaccine, and the compounds on which it was based had been tested in Europe. This defense exposes the agency’s role in converting a narrow, technically defensible claim into a much broader public belief. By accepting and authorizing the product, the Federal Drug Administration helped make semantic evasion sufficient where biological proof was required.

The agency also became part of a wider network of distributed responsibility. The manufacturers assumed that doctors, who stood to gain from prescribing the product, would not expose it; legislators had voted for acceptance; the surgeon general and the White House had political stakes in its success; and the Federal Drug Administration had already permitted it to pass. Each participant could point toward another institution, leaving no single actor willing to bear responsibility for the consequences. The agency’s procedural authority therefore helped produce a collective alibi.

Fear, Branding, and Secondary Markets

Once Phalanx had entered the market, the Federal Drug Administration’s approval gave its name credibility far beyond the original vaccine. Within six months, cheaper knockoff brands appeared, followed by products such as home and automobile air purifiers and a small device worn around the neck during air travel. These goods did not need to address the actual route of transmission. Their commercial power came from association with the approved brand and from vague language claiming that they “May Prevent Some Viral Infections.”

The episode demonstrates how regulatory legitimacy can travel through a market even when the underlying science does not. The virus was not airborne, yet the absence of airborne transmission did not prevent purifiers from selling. The approval’s symbolic force overwhelmed the distinction between demonstrated protection and the general promise of safety. The Federal Drug Administration consequently appears not merely as a failed gatekeeper but as an institution whose imprimatur helped organize an entire economy of fear.

A Broader System of Emergency Administration

The Federal Drug Administration’s conduct belongs to a larger pattern of crisis governance in which bodies are examined, classified, isolated, trained, or selected according to institutional needs. In the Israeli quarantine system, detainees endured daily testing of blood, skin, hair, saliva, urine, and feces before receiving clearance for resettlement. Elsewhere, infected people were identified by trained dogs, workers were classified according to their usefulness, and survivors were allocated to labor or military functions. Against that background, the Federal Drug Administration represents the opposite failure of expert administration: it possessed the authority to classify a medical product, but allowed political urgency and commercial incentive to replace rigorous discrimination.

That contrast gives the agency its narrative significance. Other institutions use medical or technical knowledge to impose discipline on populations; the Federal Drug Administration uses its institutional seal to authorize a story that populations want to believe. Its error is not simply that it failed to predict the epidemic. It failed at the prior task of resisting a convenient explanation, and its approval helped make that explanation socially and economically durable.